Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) SEC filings page provides access to the company’s regulatory disclosures as a public issuer. These documents include current reports on Form 8-K, periodic reports and other filings that describe clinical progress, material agreements, capital raises, governance changes and stockholder actions.
For investors tracking 4D Molecular Therapeutics’ gene therapy programs, Form 8-K filings are particularly relevant. Recent 8-Ks have covered topics such as interim clinical data from the PRISM Phase 1/2 trial of 4D-150 in wet age-related macular degeneration, updates on the AEROW trial of 4D-710 in cystic fibrosis lung disease, the collaboration and license agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets, and the appointment or transition of key executives and directors. Other 8-Ks report on equity offerings, preliminary cash and investment balances, and amendments to corporate bylaws.
Filings also disclose that 4D Molecular Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol FDMT, and they provide details on matters submitted to stockholder votes, such as director elections, auditor ratification and advisory votes on executive compensation and its frequency.
On Stock Titan, these SEC filings are updated in near real time from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key terms of collaboration and license agreements, explain the implications of financing transactions, and surface important information about clinical data disclosures, governance changes and cash runway guidance. Users can also review filings that relate to equity offerings, including underwriting agreements and pre-funded warrants, and examine how these transactions fit into 4D Molecular Therapeutics’ overall development and funding strategy.
4D Molecular Therapeutics, Inc. (FDMT) reported an insider equity transaction by its Chief Legal Officer on a Form 4. On 11/17/2025, the officer exercised a stock option to buy 1,635 shares of common stock at $4.14 per share and, on the same date, sold 1,635 shares at $10.59 per share under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these trades, the officer directly holds 3,594 shares of common stock and 75,230 stock options. The option underlying this transaction covers 1,635 shares and vests in equal monthly installments over four years starting from March 6, 2025, as long as the officer continues to serve the company.
4D Molecular Therapeutics, Inc. (FDMT) appointed Kristian Humer as its new Chief Financial Officer and Principal Financial Officer effective November 17, 2025. Humer brings experience from senior finance roles at Foghorn Therapeutics, Viridian Therapeutics, and Citigroup’s healthcare investment banking group. Under his offer letter, he receives an annual base salary of $520,000, a target annual bonus equal to 40% of base salary, a stock option to purchase 480,000 shares of common stock, and a $100,000 sign-on bonus paid in two installments with multi-year earn-out conditions tied to continued employment. If he is terminated without cause or resigns for good reason, he is eligible for severance benefits, including salary continuation and COBRA premium reimbursement, with enhanced benefits and full vesting acceleration of equity awards if such a termination occurs within 12 months after a change in control.
4D Molecular Therapeutics (FDMT) reported a larger quarterly loss as R&D spending increased. For the three months ended September 30, 2025, revenue was $90 thousand, research and development expense was $49.4 million, and general and administrative expense was $11.8 million, leading to a net loss of $56.9 million and a basic and diluted net loss per share of $1.01.
Liquidity remained solid with cash, cash equivalents and marketable securities totaling $372.2 million as of September 30, 2025. Net cash used in operating activities was $137.6 million for the nine months ended September 30, 2025. The company states these resources are sufficient to fund planned operations for at least one year from the financial statement issuance date.
As a subsequent event, in November 2025 FDMT completed an underwritten offering with net proceeds of approximately $93.3 million. As of November 7, 2025, shares outstanding were 57,135,075; an additional 10,513,949 shares were issuable upon exercise of pre-funded warrants at $0.0001 per share, subject to beneficial ownership limitations.
4D Molecular Therapeutics, Inc. filed a current report to note that it has released its financial results for the three months ended September 30, 2025. The company furnished a press release titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” as Exhibit 99.1. The filing indicates that the release also covers recent operational developments and outlines milestones the company expects in the future.
4D Molecular Therapeutics (FDMT) completed an underwritten equity offering, issuing 8,385,809 shares of common stock at $10.51 per share and pre-funded warrants for 1,128,949 shares at $10.5099 per warrant. The company reported net proceeds of approximately $93.3 million after underwriting discounts and expenses, and the transaction closed on November 7, 2025.
Underwriters purchased the shares at $9.8794 and the pre-funded warrants at $9.8793. The offering was conducted via a prospectus supplement under FDMT’s Form S-3 (effective August 15, 2023). Directors and executive officers agreed to a lock-up through January 6, 2026, subject to customary exceptions.
4D Molecular Therapeutics (FDMT) launched a primary offering of 8,385,809 shares and pre-funded warrants to purchase 1,128,949 shares at $10.51 and $10.5099, respectively. The total offering price is $99,999,993, less $6,000,006 in underwriting discounts, yielding $93,999,987 in proceeds before expenses and estimated net proceeds of approximately $93.3 million.
The company plans to fund research and development and commercialization preparations, and, together with existing cash of $372.2 million as of September 30, 2025 and expected Otsuka payments, projects funding at least into the second half of 2028. FDMT also announced an Otsuka collaboration granting APAC rights to 4D-150 with an $85.0 million upfront payment, up to $335.5 million in milestones, and tiered double‑digit royalties. Shares outstanding were 46,700,242 as of June 30, 2025.
4D Molecular Therapeutics (FDMT) reported a preliminary cash, cash equivalents and marketable securities balance of $372.2 million as of September 30, 2025. The company also announced positive interim 1.5–3.5-year data from its Phase 1/2 PRISM trial of 4D-150 in wet age-related macular degeneration.
Across cohorts, patients showed sustained reductions in supplemental anti-VEGF injections after 4D-150. In the Phase 2b recently diagnosed subgroup (Phase 3 comparable), mean supplemental injections were reduced 94% through year 1 and 92% through year 1.5. The broader Phase 2b cohort showed 83% through year 1 and 82% through year 1.5, while the Phase 1/2a severe, recalcitrant cohort showed 83% through year 1 and 79% through year 2. By 6‑month segments, the Phase 2b recently diagnosed subgroup recorded mean injections per patient of 0.1 (months 0–6), 0.2 (6–12), and 0.4 (12–18).
4D Molecular Therapeutics (FDMT) announced a collaboration and license agreement with Otsuka Pharmaceutical granting Otsuka exclusive rights to develop and commercialize 4D-150 for ophthalmological diseases in Japan, China, Australia and other APAC markets. The Company will continue to lead all Phase 3 clinical activity globally, while Otsuka will lead regulatory and commercialization in its territories.
Financial terms include an $85 million upfront cash payment, expected cost sharing of at least $50 million over the next three years for global development, eligibility for up to $335.5 million in potential regulatory and commercial milestones, and tiered double-digit royalties on net sales in Otsuka’s territories. 4DMT retains full rights outside APAC, including the U.S., Latin America and Europe.
Operationally, APAC sites in 4FRONT-2 (global Phase 3 in wet AMD) are expected to open by year-end, with Japan sites expected to open in January 2026. Enrollment in 4FRONT-1 continues to exceed initial expectations, with over 200 patients randomized as of October 30, 2025. The agreement includes customary governance via a joint steering committee and standard termination and indemnity provisions.
4D Molecular Therapeutics (FDMT) reported an insider transaction by its Chief Legal Officer. On 10/24/2025, the officer exercised 1,084 stock options at $6.49 per share and sold 2,678 common shares at $12 per share under a Rule 10b5-1 plan adopted on June 6, 2025.
Following these transactions, the officer beneficially owned 3,594 common shares directly. The filing also shows 9,295 stock options beneficially owned after the reported activity, with the option grant expiring on 06/17/2032 and vesting monthly from the June 16, 2022 commencement date until the fourth anniversary.
4D Molecular Therapeutics (FDMT) Form 4: the Chief Legal Officer reported an option exercise and a same‑day sale on 10/16/2025. The insider exercised 1,635 stock options at $4.14 per share (Code M) and sold 1,635 common shares at $10.17 per share (Code S) pursuant to a Rule 10b5‑1 plan adopted on June 6, 2025.
Following these transactions, the insider reported 5,188 common shares directly owned and 76,865 derivative securities (stock options) beneficially owned. The exercised option was part of an award vesting monthly in 1/48th increments starting March 6, 2025, with full vesting on the fourth anniversary, and carries an expiration date of March 5, 2035.